

**Fig. S3. Upregulation of FN1 in human melanoma xenografts and in a metastatic melanoma cell line treated with anle138b.**

(A) A tissue section from a non-treated WM983-B tumor xenograft probed with an antibody to human FN1 (pseudocolored green) and counterstained with fluorescent DAPI (pseudocolored blue). Scale bar - 50  $\mu\text{m}$ . (B) A tissue section from a WM983-B tumor xenograft that had been treated with anle138b for six days, probed with an antibody to human FN1 (pseudocolored green) and counterstained with fluorescent DAPI (pseudocolored blue). Scale bar - 50  $\mu\text{m}$ . (C) Immunoblot analysis of WM983-B metastatic melanoma cells that were treated with 10  $\mu\text{M}$  of anle138b for 48 h or 72 h, with replenishment of 10  $\mu\text{M}$  of the compound at 48 h. The immunoblot was probed with an antibody to human FN1 and an anti-GAPDH antibody for loading control. (D) Protein-protein interaction networks, identified in the STRING database, of proteins identified as significantly enriched in the anle138b-treated compared with the non-treated WM983-B human melanoma xenografts.

**Fig. S3**

